- Home
- MTLS vs DMAC Comparison
MTLS vs DMAC Comparison
Compare MTLS & DMAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MTLS
- DMAC
- Stock Information
- Founded
- MTLS 1990
- DMAC 2000
- Country
- MTLS Belgium
- DMAC United States
- Employees
- MTLS N/A
- DMAC N/A
- Industry
- MTLS Computer Software: Prepackaged Software
- DMAC Biotechnology: Pharmaceutical Preparations
- Sector
- MTLS Technology
- DMAC Health Care
- Exchange
- MTLS Nasdaq
- DMAC Nasdaq
- Market Cap
- MTLS 297.1M
- DMAC 267.7M
- IPO Year
- MTLS 2014
- DMAC N/A
- Fundamental
- Price
- MTLS $5.16
- DMAC $4.28
- Analyst Decision
- MTLS Buy
- DMAC Strong Buy
- Analyst Count
- MTLS 1
- DMAC 3
- Target Price
- MTLS $9.50
- DMAC $8.00
- AVG Volume (30 Days)
- MTLS 239.5K
- DMAC 76.0K
- Earning Date
- MTLS 04-24-2025
- DMAC 03-17-2025
- Dividend Yield
- MTLS N/A
- DMAC N/A
- EPS Growth
- MTLS 106.79
- DMAC N/A
- EPS
- MTLS 0.24
- DMAC N/A
- Revenue
- MTLS $276,182,835.00
- DMAC N/A
- Revenue This Year
- MTLS $6.55
- DMAC N/A
- Revenue Next Year
- MTLS $9.21
- DMAC N/A
- P/E Ratio
- MTLS $21.95
- DMAC N/A
- Revenue Growth
- MTLS 4.15
- DMAC N/A
- 52 Week Low
- MTLS $4.70
- DMAC $2.14
- 52 Week High
- MTLS $9.69
- DMAC $6.82
- Technical
- Relative Strength Index (RSI)
- MTLS 37.42
- DMAC 28.27
- Support Level
- MTLS $5.01
- DMAC $5.49
- Resistance Level
- MTLS $5.46
- DMAC $5.12
- Average True Range (ATR)
- MTLS 0.18
- DMAC 0.35
- MACD
- MTLS 0.12
- DMAC -0.13
- Stochastic Oscillator
- MTLS 59.32
- DMAC 0.31
About MTLS Materialise NV
Materialise NV is a provider of 3D printing services. The products and services of the group are organized in three segments: Medical segment, which develops and delivers medical software solutions, medical devices, and other related products and services; Software segment, which develops and delivers additive manufacturing software solutions and related services; and Manufacturing segment, which delivers 3D printed products and related services. Its geographical segments are the United States, the Americas (excluding the USA), Belgium, Germany, Poland, France, Switzerland, the United Kingdom, Italy, the Netherlands, Other Europe, and the Asia Pacific.
About DMAC DiaMedica Therapeutics Inc.
DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is principally engaged in the business activity of developing treatments for unmet clinical needs or where no therapies are available with a primary focus on chronic kidney disease and acute ischemicstroke. Its pipeline product DM199 is a recombinant form of human tissue kallikrein-1.